In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Vertex Pharmaceuticals, with a price target of $460.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mohit Bansal’s rating is based on several factors impacting Vertex Pharmaceuticals. The recent data on VX-993 did not meet expectations, showing weaker results compared to VX-548. This suggests that Vertex might have already achieved the optimal dose response with VX-548, and further improvements may be challenging without new combinations.
Additionally, the company’s decision to not pursue a Phase 3 trial for a broader chronic pain label and instead focus on a narrower diabetic peripheral neuropathy (DPN) label could limit market opportunities. This shift in strategy may delay potential market entry by 2-3 years, affecting the company’s growth prospects in the chronic pain segment. Despite some positive sales figures for other products, these concerns contribute to the Hold rating.
In another report released on August 1, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $480.00 price target.